Update: The comparison chart was last updated September, 2020.
As more biosimilars continue to be approved across the world, it is helpful to compare the applicable regimes across major jurisdictions. We have collaborated with Brian Coggio of Fish & Richardson, and Mary Foord-Weston and Camilla Balleny of Carpmaels & Ransford to prepare the chart below comparing relevant considerations for biosimilars in Canada, the US, and Europe, including regulatory pathways, data protection and patent linkage.
Related Publications & Articles
-
Federal Court of Appeal upholds invalidity of Lilly’s CIALIS patent extending to “physiologically acceptable salt”
The Federal Court of Appeal dismissed an appeal by Lilly from a decision of the Federal Court which had granted a motion for summary trial brought by Teva, Pharmascience, Laboratoire Riva, Apotex and ...Read More -
CIPO will not issue patents on July 9 or July 16
The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More